Synapse - Shanu Modi

Results (19)

Final analysis of consolidative use of radiotherapy to block (CURB) oligoprogression trial - A randomized study of stereotactic body radiotherapy for oligoprogressive metastatic lung and breast cancers

Meeting Abstract

Tsai, C. J.; Yang, J. T.; Guttmann, D. M.; Shaverdian, N.; Eng, J.; Yeh, R.; Girshman, J.; Das, J.; Gelblum, D.; Xu, A. J.; more...
International Journal of Radiation Oncology, Biology, Physics (2022)

Fulltext@MSK | Save

Consolidative use of radiotherapy to block (CURB) oligoprogression: Interim analysis of the first randomized study of stereotactic body radiotherapy in patients with oligoprogressive metastatic cancers of the lung and breast

Meeting Abstract

Tsai, C. J.; Yang, J. T.; Guttmann, D. M.; Shaverdian, N.; Shepherd, A. F.; Eng, J.; Gelblum, D.; Xu, A. J.; Namakydoust, A.; Iqbal, A.; more...
International Journal of Radiation Oncology, Biology, Physics (2021)

Fulltext@MSK | Save

Immunomodulatory activity of a colony-stimulating factor-1 receptor inhibitor in patients with advanced refractory breast or prostate cancer: A phase I study

Journal Article

Autio, K. A.; Klebanoff, C. A.; Schaer, D.; Kauh, J. S. W.; Slovin, S. F.; Adamow, M.; Blinder, V. S.; Brahmachary, M.; Carlsen, M.; Comen, E.; more...
Clinical Cancer Research (2021)

Fulltext@MSK | Save

Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors

Journal Article

Razavi, P.; Dickler, M. N.; Shah, P. D.; Toy, W.; Brown, D. N.; Won, H. H.; Li, B. T.; Shen, R.; Vasan, N.; Modi, S.; more...
Nature Cancer (2020)

Fulltext@MSK | Save

Measuring tumor epichaperome expression using [(124)I] PU-H71 positron emission tomography as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2-negative metastatic breast cancer

Journal Article

Jhaveri, K. L.; dos Anjos, C. H.; Taldone, T.; Wang, R.; Comen, E.; Fornier, M.; Bromberg, J. F.; Ma, W.; Patil, S.; Rodina, A.; more...
JCO Precision Oncology (2020)

Fulltext@MSK | Save

Tumor epichaperome expression using (124)I PU-H71 PET (PU-PET) as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2 negative (HER2-) metastatic breast cancer (MBC)

Meeting Abstract

Jhaveri, K.; Dunphy, M.; Wang, R.; Comen, E.; Fornier, M.; Moynahan, M. E.; Bromberg, J.; Ma, W.; Patil, S.; Taldone, T.; more...
Cancer Research (2019)

Fulltext@MSK | Save

Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)

Meeting Abstract

Shah, P. D.; Moynahan, M. E.; Modi, S.; Hamilton, N.; Caravella, B. A.; Zamora, S.; Dang, C.; Gilewski, T.; Traina, T.; Comen, E.; more...
Cancer Research (2015)

Fulltext@MSK | Save

Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)

Meeting Abstract

Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
Cancer Research (2015)

Fulltext@MSK | Save

Phase I trial of daily PI3K alpha inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)

Meeting Abstract

Shah, P. D.; Modi, S.; Datko, F. M.; Moynahan, M. E.; Zamora, S.; D'Andrea, G.; Lake, D.; Goldfarb, S. B.; Patil, S.; Singh, S.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors

Journal Article

Jhaveri, K.; Miller, K.; Rosen, L.; Schneider, B.; Chap, L.; Hannah, A.; Zhong, Z.; Ma, W.; Hudis, C.; Modi, S.
Clinical Cancer Research (2012)

Fulltext@MSK | Save